Citation Impact
Citing Papers
Histone demethylase KDM6A directly senses oxygen to control chromatin and cell fate
2019 StandoutScienceNobel
DNA Damage–Specific Control of Cell Death by Cryptochrome in p53-Mutant Ras–Transformed Cells
2012 StandoutNobel
Breast and Ovarian Cancer Risks Due to Inherited Mutations in BRCA1 and BRCA2
2003 StandoutScience
( R )-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible
2013 StandoutScienceNobel
Mutation Analysis of Isocitrate Dehydrogenase in Acute Lymphoblastic Leukemia
2012
Hallmarks of Cancer: The Next Generation
2011 Standout
IDH mutations in primary myelofibrosis predict leukemic transformation and shortened survival: clinical evidence for leukemogenic collaboration with JAK2V617F
2011
Mutation analysis of P73 and TP53 in Merkel cell carcinoma
2000
Chemosensitivity linked to p73 function
2003 StandoutNobel
Nucleotide Binding by the MDM2 RING Domain Facilitates Arf-Independent MDM2 Nucleolar Localization
2003 StandoutNobel
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
2005 StandoutNobel
A common polymorphism acts as an intragenic modifier of mutant p53 behaviour
2000 StandoutNobel
p73 at chromosome 1p36.3 is lost in advanced stage neuroblastoma but its mutation is infrequent
1999
Role for the p53 homologue p73 in E2F-1-induced apoptosis
2000 StandoutNatureNobel
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
2002 Standout
Expression of p73 and Its Relation to Histopathology and Prognosis in Hepatocellular Carcinoma
1999
JAK Inhibition with Ruxolitinib versus Best Available Therapy for Myelofibrosis
2012 Standout
An overview on CALR and CSF3R mutations and a proposal for revision of WHO diagnostic criteria for myeloproliferative neoplasms
2014
Cancer-associated IDH mutations: biomarker and therapeutic opportunities
2010
Mutational analysis of thep73Gene in human breast cancers
1999
Oncogenic kinase signalling
2001 StandoutNature
Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: a Mayo Clinic Study of 277 patients
2011
Infrequent somatic mutations of thep73genein various human cancers
1999
Lack ofp73 mutations and late occurrence ofp73 allelic deletions in melanoma tissues and cell lines
1999
p53 family genes: structural comparison, expression and mutation
1999
Mutations in AXIN2 Cause Familial Tooth Agenesis and Predispose to Colorectal Cancer
2004
Control of β-Catenin Phosphorylation/Degradation by a Dual-Kinase Mechanism
2002 Standout
Choosing anticancer drug targets in the postgenomic era
1999 StandoutNobel
IDH mutations in glioma and acute myeloid leukemia
2010
The prognostic impact and stability of Isocitrate dehydrogenase 2 mutation in adult patients with acute myeloid leukemia
2010
Regulation of β-Catenin Signaling in the Wnt Pathway
2000
The Human p73 Promoter: Characterization and Identification of Functional E2F Binding Sites
2002 StandoutNobel
A GSK3β Phosphorylation Site in Axin Modulates Interaction with β-Catenin and Tcf-Mediated Gene Expression
1999
The p53 pathway
1999
IDH mutations in acute myeloid leukemia
2012
Clinical Implications of Novel Mutations in Epigenetic Modifiers in AML
2011
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
2016 Standout
Fumarate and Succinate Regulate Expression of Hypoxia-inducible Genes via TET Enzymes
2015 StandoutNobel
What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer
2013 StandoutNobel
Dynamic RNA Modifications in Gene Expression Regulation
2017 Standout
Cancer genes and the pathways they control
2004 Standout
Transactivation-deficient ΔTA-p73 Inhibits p53 by Direct Competition for DNA Binding
2002
Oncogenes Induce and Activate Endogenous p73 Protein
2001
Wnt/β-Catenin Signaling and Disease
2012 Standout
The expression of p73 is increased in lung cancer, independent of p53 gene alteration
1999
p73 gene transcripts in human brain tumors: overexpression and altered splicing in ependymomas
1999
Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating β-catenin/TCF signalling
2000
Gene Silencing in Cancer in Association with Promoter Hypermethylation
2003 Standout
Physical and Functional Interaction between p53 Mutants and Different Isoforms of p73
2000
The p53 gene family
1999 StandoutNobel
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
2011 Standout
Wnt/β-Catenin Signaling in Development and Disease
2006 Standout
Molecular Cloning and Functional Characterization of the Upstream Promoter Region of the Human p73 Gene
1999
TET2 promoter methylation in low-grade diffuse gliomas lacking IDH1/2 mutations: Figure 1
2011
p63 and p73: old members of a new family
2000 StandoutNobel
Understanding the Intersections between Metabolism and Cancer Biology
2017 Standout
DNA damage induces transcriptional activation of p73 by removing C-EBP repression on E2F1
2003
The large T antigen of simian virus 40 binds and inactivates p53 but not p73.
1998
5-hydroxymethylcytosine in cancer: significance in diagnosis and therapy
2015
Expression of p73, a novel protein related to the p53 tumour suppressor p53, and apoptosis in cholangiocellular carcinoma of the liver
1999
Role of the newer p53 family proteins in malignancy
2001 StandoutNobel
Modulation of Wnt signaling by Axin and Axil
1999
Alterations of p73 preferentially occur in gastric adenocarcinomas with foveolar epithelial phenotype
1999
Seven-transmembrane receptors
2002 StandoutNobel
Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia
2012
The Emerging p53 Gene Family
1999 StandoutNobel
A common E2F-1 and p73 pathway mediates cell death induced by TCR activation
2000 StandoutNatureNobel
Wnt signalling in stem cells and cancer
2005 StandoutNature
Inactivation of the p53-homologue p73 by the mdm2-oncoprotein
1999
On the shoulders of giants: p63, p73 and the rise of p53
2002
Analysis of p73 in human borderline and invasive ovarian tumor
2000
Allelic expression of the putative tumor suppressor gene p73 in human fetal tissues and tumor specimens
2000
Promoter specificity and stability control of the p53-related protein p73
1999
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
2001 Standout
Molecular alterations of p73 in human esophageal squamous cell carcinomas: loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53
2000
Wnt/β-Catenin Signaling, Disease, and Emerging Therapeutic Modalities
2017 Standout
Brain Tumors
2001 Standout
Head and Neck Cancer
2001 Standout
The kinesin KIF1Bβ acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor
2008 StandoutNobel
p73: Friend or foe in tumorigenesis
2002
Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes
2011
Wnt/β-Catenin/Tcf Signaling Induces the Transcription of Axin2, a Negative Regulator of the Signaling Pathway
2002
P73 gene expression in ovarian cancer tissues and cell lines.
2000
Overexpression of the wild type p73 gene in breast cancer tissues and cell lines.
1999
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Mouse p73 gene maps to the distal part of chromosome 4 and might be involved in the progression of gamma-radiation-induced T-cell lymphomas.
1999
Accumulation of the FACT complex, as well as histone H3.3, serves as a target marker for somatic hypermutation
2013 StandoutNobel
Expression level, allelic origin, and mutation analysis of the p73 gene in neuroblastoma tumors and cell lines.
1998
Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas
2000
Prognostic irrelevance of ring sideroblast percentage in World Health Organization–defined myelodysplastic syndromes without excess blasts
2012
Role of the p53-homologue p73 in E2F1-induced apoptosis
2000
Mutational and expression analysis of the p73 gene in melanoma cell lines.
1999
DNA Mismatch Repair: Functions and Mechanisms
2005 StandoutNobel
MDM2 Suppresses p73 Function without Promoting p73 Degradation
1999 StandoutNobel
Inhibition of Adipogenesis by Wnt Signaling
2000 StandoutScience
Increased Wnt Signaling During Aging Alters Muscle Stem Cell Fate and Increases Fibrosis
2007 StandoutScience
Loss of p73 gene expression in leukemias/lymphomas due to hypermethylation.
1999
Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5' CpG island methylation.
1999
Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses
2001 Standout
A Subset of Tumor-Derived Mutant Forms of p53 Down-Regulate p63 and p73 through a Direct Interaction with the p53 Core Domain
2001
Distinct expression patterns of the p53-homologue p73 in malignant and normal hematopoiesis assessed by a novel real-time reverse transcription-polymerase chain reaction assay and protein analysis.
1999
New mutations and pathogenesis of myeloproliferative neoplasms
2011
Surfing the p53 network
2000 StandoutNature
The Regulator of G Protein Signaling Family
2000
Failure of viral oncoproteins to target the p53-homologue p51A
1999
Efficacy of Bilateral Prophylactic Mastectomy in BRCA1 and BRCA2 Gene Mutation Carriers
2001
Mutational analysis of the p63/p73L/p51/p40/CUSP/KET gene in human cancer cell lines using intronic primers.
1999
p53 family update: p73 and p63 develop their own identities.
2001 StandoutNobel
The Definition of Primary and Secondary Glioblastoma
2012
IDH mutations in Primary Myelofibrosis Predict Leukemic Transformation and Shortened Survival: Clinical Evidence for Leukemogenic Collaboration with JAK2V617F
2011
AIS is an oncogene amplified in squamous cell carcinoma
2000
Elevated and biallelic expression of p73 is associated withprogression of human bladder cancer.
1999
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
2016 Standout
Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73.
2002
Frequent alteration of p63 expression in human primary bladder carcinomas.
2000
Works of Ming Mai being referenced
IDH1 and IDH2 mutation studies in 1473 patients with chronic-, fibrotic- or blast-phase essential thrombocythemia, polycythemia vera or myelofibrosis
2010
IDH1 and IDH2 mutation analysis in chronic- and blast-phase myeloproliferative neoplasms
2010
Cloning of the Human Homolog of Conductin (AXIN2), a Gene Mapping to Chromosome 17q23–q24
1999
Loss of imprinting and allele switching of p73 in renal cell carcinoma
1998
Overexpression of the wild type p73 gene in human bladder cancer
1999
p73 mutations are not detected in sporadic and hereditary breast cancer
1999
Genomic Organization and Mutation Analysis ofp73in Oligodendrogliomas with Chromosome 1 p-Arm Deletions
1998
Mutation and expression analysis of thep73 gene in prostate cancer
1999
Differential expression and allelotyping of the p73 gene in neuroblastoma.
2000
Activation of p73 silent allele in lung cancer.
1998
Mutation and expression analysis of the p73 gene in prostate cancer
1999